Ideas to action: independent research for global prosperity
Search
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Content Type
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
March 13, 2024
When world leaders gather in September for this year’s UN General Assembly, antimicrobial resistance (AMR) will be on the agenda. For people like me who care passionately about this issue, this is a welcome opportunity to address a global problem with a global solution. Ahead of September, we need t...
Blog Post
February 22, 2024
The process of discovering, producing, buying, and consuming antibiotics is riddled with market and government failures. To solve antibiotic resistance, it’s not enough to solve just some of these. If we fix the market failures that reduce the number of new antibiotics that are discovered, but not t...
WORKING PAPERS
February 22, 2024
Antibiotic resistance (ABR) already contributes to almost five million deaths per year. Without action, this number will likely rise substantially. We provide the first comprehensive assessment of the economic drivers of ABR, arguing that ABR in large part arises from extensive unresolved market (an...
Blog Post
September 21, 2023
The politics of antimicrobial resistance (AMR) has changed substantially since we launched the first CGD working group on AMR in 2007. There is now much more awareness about the need to act, even if global solutions have not yet been implemented. Countries including the UK, Canada, and Japan have an...
REPORTS
September 20, 2023
In our final working group report, we outline the principles of a Grand Bargain that we believe all stakeholders can and should sign up to during the UN General Assembly's High-Level Meeting on antimicrobial resistance in 2024. Explore our recommendations on increasing the availability of critically...
POLICY PAPERS
August 07, 2023
A main driver of antimicrobial resistance is the misuse and overuse of antimicrobials. But lack of access to antimicrobials causes a large mortality burden and contributes to the spread of resistant infections. How can learnings from the use of control policies in other areas of medicine be translat...
Blog Post
August 07, 2023
In a new paper, we argue that the idea of “stewardship”—and the tension between some stewardship policies and patient access—extends well beyond antimicrobials, to all drug classes. We consider the many reasons why governments opt to impose controls on medicines, and how rationales for control relat...
BRIEFS
July 31, 2023
India is racing against the clock in its fight against antimicrobial resistance. A combination of complex regulatory and procurement systems, a lack of health insurance penetration, and little groundwork on state and national action plans has stymied progress. A multifold approach is needed to impro...
BRIEFS
June 08, 2023
Facing the high—and rising—burden of antimicrobial resistance (AMR), Brazil has an opportunity to improve access, stewardship, and innovation for critical antimicrobials at the national, regional, and/or global level(s) by modifying procurement arrangements. Brazil is positioned for significant dome...
Blog Post
May 24, 2023
The Working Group has been built on existing proposals and initiatives which people from across the AMR space have kindly taken the time to share with us during the last 18 months. Indeed, more than 60 percent of people that we interviewed as part of our Landscape Review highlighted the need for a b...